Table 1. Competition Binding.
|
3H DPDPE (20 nM) pKi ± SEM |
||
|---|---|---|
| MOR/DOR | DOR | |
| L2 | 7.34 ± 0.06 | 6.69 ± 0.18 |
| Oxy | 6.29 ± 0.10 | 6.14 ± 0.09 |
| ENTI | 7.46 ± 0.09 | 7.04 ± 0.21 |
| NTI | 8.26 ± 0.15 | 8.58 ± 0.23 |
| L4 | 8.60 ± 0.07 | 7.70 ± 0.11 |
| SNC-19 | 5.78 ± 0.14 | 5.54 ± 0.20 |
| SNC80 | 8.11 ± 0.13 | 7.78 ± 0.23 |
| NTX-19 | 7.79 ± 0.11 | 7.51 ± 0.10 |
|
3H DAMGO (10 nM) pKi ± SEM |
||
|---|---|---|
| MOR | MOR/DOR | |
| L2 | 8.01 ± 0.05 | 8.21 ± 0.01 |
| Oxy | 8.30 ± 0.03 | 8.33 ± 0.07 |
| MA-19 | 7.65 ± 0.06 | 6.90 ± 0.11 |
| ENTI | 6.92 ± 0.16 | 6.94 ± 0.08 |
| NTI | 7.78 ± 0.12 | 8.46 ± 0.14 |
| L4 | >9 | >9 |
| SNC-19 | 6.26 ± 0.15 | 5.92 ± 0.07 |
| NTX-19 | 9.49 ± 0.11 | 8.38 ± 0.04 |
| naltrexone | 9.19 ± 0.23 | 9.06 ± 0.32 |